Heme oxygenase improves renal function by potentiating podocyte-associated proteins in N ω-nitro-l-arginine-methyl ester (l-NAME)-induced hypertension

American Journal of Hypertension

Volumn 28, Issue 7, 2015, Pages 930-942

  Ndisang, Joseph Fomusi ^a   Chibbar, Rajni ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

adiponectin; atrial natriuretic peptide; blood pressure; CD2 associated protein; extracellular matrix; heme oxygenase; hypertension; inflammation; nephrin; nephropathy; oxidative stress; podocalyxin; podocin

Indexed keywords

8 ISOPROSTANE; ADIPONECTIN; ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; CD2 ASSOCIATED PROTEIN; COLLAGEN; CYCLIC GMP; ENDOTHELIN 1; FIBRONECTIN; HEME ARGINATE; HEME OXYGENASE; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G) NITROARGININE METHYL ESTER; NEPHRIN; PODOCALYXIN; PODOCIN; SODIUM; TUMOR NECROSIS FACTOR ALPHA; ARGININE; AUTACOID; BIOLOGICAL MARKER; CHROMIUM MESOPORPHYRIN; ENZYME INHIBITOR; HEME; HMOX1 PROTEIN, RAT; MESOPORPHYRIN; SCLEROPROTEIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE CLEARANCE; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; FLUID INTAKE; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MONONUCLEAR CELL; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION; SODIUM BLOOD LEVEL; SODIUM EXCRETION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL PROTECTION; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; FIBROSIS; KIDNEY; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; ARGININE; BIOMARKERS; CYTOPROTECTION; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; ENZYME INHIBITORS; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; HEME; HEME OXYGENASE (DECYCLIZING); HYPERTENSION; INFLAMMATION MEDIATORS; KIDNEY; MALE; MESOPORPHYRINS; NG-NITROARGININE METHYL ESTER; OXIDATIVE STRESS; PODOCYTES; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84936753928     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu240     Document Type: Article

References (35)

1. Nugent RA, Fathima SF, Feigl AB, Chyung D. The burden of chronic kidney disease on developing nations: a 21st century challenge in global health. Nephron Clin Pract 2011; 118:c269-c277.
2. Murray CJ, Richards M. A., Newton JN, Fenton KA, Anderson HR, Atkinson C, Bennett D, BernabE, Blencowe H, Bourne R, Braithwaite T, Brayne C, Bruce NG, Brugha TS, Burney P, Dherani M, Dolk H, Edmond K, Ezzati M, Flaxman AD, Fleming TD, Freedman G, Gunnell D, Hay RJ, Hutchings SJ, Ohno SL, Lozano R, Lyons RA, Marcenes W, Naghavi M, Newton CR, Pearce N, Pope D, Rushton L, Salomon JA, Shibuya K, Vos T, Wang H, Williams HC, Woolf AD, Lopez AD, Davis A. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet 2013; 381:997-1020.
3. Navarro-Gonzez JF, Mora-Ferndez C, Muros de Fuentes M, Garc-Pez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol 2011; 7:327-340.
4. Singh DK, Winocour P, Farrington K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 2011; 7:176-184.
5. Lo DJ, Weaver TA, Kleiner DE, Mannon RB, Jacobson LM, Becker BN, Swanson SJ, Hale DA, Kirk AD. Chemokines and their receptors in human renal allotransplantation. Transplantation 2011; 91:70-77.
6. Wang Y, Wang DH. Protective effect of TRPV1 against renal fibrosis via inhibition of TGF-/Smad signaling in DOCA-salt hypertension. Mol Med 2011; 17:1204-1212.
7. Jim B, Ghanta M, Qipo A, Fan Y, Chuang PY, Cohen HW, Abadi M, Thomas DB, He JC. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One 2012; 7:e36041.
8. Marshall SM. The podocyte: a potential therapeutic target in diabetic nephropathy Curr Pharm Des 2007; 13:2713-2720.
9. Menne J, Meier M, Park JK, Boehne M, Kirsch T, Lindschau C, Ociepka R, Leitges M, Rinta-Valkama J, Holthofer H, Haller H. Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C alpha signaling in-vivo. Kidney Int 2006; 70:1456-1462.
10. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium Diabetologia 2008; 51:714-725.
11. Nakatsue T, Koike H, Han GD, Suzuki K, Miyauchi N, Yuan H, Salant DJ, Gejyo F, Shimizu F, Kawachi H. Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney Int 2005; 67:2239-2253.
12. Ndisang JF. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm 2010; 2010:359732.
13. Ndisang JF, Lane N, Syed N, Jadhav A. Up-regulating the heme oxygenase system with hemin improves insulin sensitivity and glucose metabolism in adult spontaneously hypertensive rats. Endocrinology 2010; 151:549-560.
14. Ikeda H, Tsuruya K, Toyonaga J, Masutani K, Hayashida H, Hirakata H, Iida M. Spironolactone suppresses inflammation and prevents l-NAME-induced renal injury in rats. Kidney Int 2009; 75:147-155.
15. Lane N, Ndisang J. Heme-L-arginate therapy suppresses angiotensin levels in L-name-induced hypertension. Can J Cardiol 2007; 23:246C-246C.
16. Tanir HM, Sener T, Inal M, Akyuz F, Uzuner K, Sivri E. Effect of quercetine and glutathione on the level of superoxide dismutase, catalase, malonyldialdehyde, blood pressure and neonatal outcome in a rat model of pre-eclampsia induced by NG-nitro-L-arginine-methyl ester. Eur J Obstet Gynecol Reprod Biol 2005; 118:190-195.
17. Jadhav A, Ndisang JF. Heme arginate suppresses cardiac lesions and hypertrophy in deoxycorticosterone acetate-salt hypertension. Exp Biol Med (Maywood) 2009; 234:764-778.
18. Jadhav A, Ndisang JF. Treatment with heme arginate alleviates adipose tissue inflammation and improves insulin sensitivity and glucose metabolism in a rat model of Human primary aldosteronism. Free Radic Biol Med 2012; 53:2277-2286.
19. Ndisang JF, Jadhav A. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension. J Pharmacol Exp Ther 2010; 334:87-98.
20. Ndisang JF, Jadhav A. Heme-arginate suppresses phospholipase C and oxidative stress in the mesenteric arterioles of mineralocorticoidinduced hypertensive rats. Hypertens Res 2010; 33:338-347.
21. Vreman HJ, Ekstrand BC, Stevenson DK. Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity. Pediatr Res 1993; 33:195-200.
22. Ndisang JF, Jadhav A, Lane N. Interaction between the heme oxygenase system and aldosterone in hypertension. Int J Angiol 2007; 16:92-97.
23. Ndisang JF, Lane N, Jadhav A. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 2009; 296:E1029-E1041.
24. Jadhav A, Tiwari S, Lee P, Ndisang JF. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats. J Pharmacol Exp Ther 2013; 345:239-249.
25. Ndisang JF, Wang R. Age-related alterations in soluble guanylyl cyclase and cGMP pathway in spontaneously hypertensive rats. J Hypertens 2003; 21:1117-1124.
26. Benigni A, Zoja C, Zatelli C, Corna D, Longaretti L, Rottoli D, Maggioni P, Todeschini M, Noris M, Remuzzi G. Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney Int 2004; 66:1959-1965.
27. Ndisang JF, Tabien HE, Wang R. Carbon monoxide and hypertension. J Hypertens 2004; 22:1057-1074.
28. Wang Y, Krer S, Loof T, Martini S, Kron S, Kawachi H, Shimizu F, Neumayer HH, Peters H. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int 2005; 68:47-61.
29. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 2008; 118:1645-1656.
30. Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, Jordan J. Atrial natriuretic peptide and adiponectin interactions in man. PLoS One 2012; 7:e43238.
31. Kiemer AK, Bildner N, Weber NC, Vollmar AM. Characterization of heme oxygenase 1 (heat shock protein 32) induction by atrial natriuretic peptide in human endothelial cells. Endocrinology 2003; 144:802-812.
32. Polte T, Hemmerle A, Berndt G, Grosser N, Abate A, Schrer H. Atrial natriuretic peptide reduces cyclosporin toxicity in renal cells: role of cGMP and heme oxygenase-1. Free Radic Biol Med 2002; 32:56-63.
33. Riba R, Patel B, Aburima A, Naseem KM. Globular adiponectin increases cGMP formation in blood platelets independently of nitric oxide. J Thromb Haemost 2008; 6:2121-2131.
34. Piechota M, Banach M, Irzmaski R, Misztal M, Rysz J, Barylski M, Piechota-Urbaska M, Kowalski J, Pawlicki L. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients. Cell Mol Biol Lett 2007; 12:162-175.
35. Sechi LA, Valentin JP, Griffin CA, Lee E, Bartoli E, Humphreys MH, Schambelan M. Receptors for atrial natriuretic peptide are decreased in the kidney of rats with streptozotocin-induced diabetes mellitus. J Clin Invest 1995; 95:2451-2457.